Phone: (919) 684-2611
3552, Blue Zone, Duke South
Durham, NC 27710
Email: kaddu001 AT mc DOT duke DOT edu
Psychiatry & Behavioral Sciences, School of Medicine
Dr. Kaddurah-Daouk is one of the pioneers in the field of metabolomics. She leads an NIH funded network that includes seventeen academic centers with comprehensive metabolomics, informatics and pathway analysis capabilities.
Metabolomics, the newest of the omics approaches provides powerful tools for defining perturbations in metabolic pathways and networks in human disease (Kaddurah-Daouk, et al 2008; 2009). The metabolome defines a metabolic state as regulated by net interactions between gene and environment influences and provides information that can possibly bridge the gap between genotype and phenotype. It provides a missing piece to a systems approach to the study of diseases of the central nervous system. Metabolic signatures for CNS disorders could result in the identification of biomarkers for disease, for disease progression or for response to therapy. Additionally metabolomics provides powerful tools for the process of drug discovery and drug development by providing detailed biochemical knowledge about drug candidates their mechanism of action, therapeutic potential and side effects.
Research Scientist, Massachusetts Institute of Technology, Biology, 1988-1990
Research Fellow, Massachusetts General Hospital, Harvard Medical School, Molecular Biology & Genetics, 1985-1988
Postdoctoral Fellow, Johns Hopkins School of Medicine, Molecular Biology & Genetics, 1983-1985
Ph.D., American University of Beirut (Lebanon), Biochemistry, 1983
B.S., American University of Beirut (Lebanon), Chemistry, 1978
Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R (2011). Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One ; 6:e21643. Epub 2011.
Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E,, Krishnan RR, Rush AJ, Pickering E and Delnomdedieu M (2011). Pretreatment Metabotype as a Predictor of Response to Sertraline or Placebo in Depressed Outpatients: A Proof of Concept. Translational Psychiatry 1, e26; doi:10.1038/tp.2011.22.
Ji Y, Hebbring S, Zhu H, Jenkins GD, Biernacka J, Snyder K, Drews M, Fiehn O, Zeng Z, Schaid D, Mrazek DA, Kaddurah-Daouk R, Weinshilboum RM (2011). Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther. 2011 Jan;89(1):97-104.
Copyright 2008-2013 DIBS and Duke University. All rights reserved.